Clinical trial

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

NCT03060356

Study summary

ClinicalTrials.gov

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: EARLY_PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention T cells modified with RNA anti -cMET CAR Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2016-12-21

PhaseEARLY_PHASE1

Conditions

Malignant Melanomaverified · MONDO: melanoma

Breast Cancerverified · MONDO: breast cancer

Interventions

T cells modified with RNA anti -cMET CARBIOLOGICAL

Sponsors & collaborators

University of Pennsylvanialead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03060356 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.